ProstaGene, a biotech startup, develops patented cancer treatments and gene-based prostate testing technologies, seeking financing for commercialization.
ProstaGene is a biotechnology startup focused on developing innovative cancer treatments and gene-based prostate testing technologies. Founded by Dr. Richard G. Pestell, the company integrates proprietary molecular diagnostics with novel therapeutic screening to create advanced cancer therapies. ProstaGene aims to commercialize its technologies through contracted development, partnering, and out-licensing.
ProstaGene has achieved significant milestones in securing patents for its unique technologies, positioning itself as a promising player in the biotech industry. The company is actively seeking financing to recruit a CEO and further its commercialization efforts. Dr. Richard G. Pestell's expertise and leadership have been pivotal in the company's progress and vision.
